MORC3 and retinitis pigmentosa 1: Studies have been found successful tocilizumab treatment of RP-ILD in anti-MDA5 antibody-positive DM patients [33]; we have also successfully treated an NXP-2 antibody-positive DM patient with tocilizumab [34].